Bli medlem
Bli medlem

Du är här


Redeye: IRRAS - Estimates Revision

Redeye returns with updated estimates following IRRAS’s Q3 2021 report. In short, the company is heading in the right direction activity-wise, with substantial sales growth now apparent. However, we lower our sales estimates for the coming years, adjusting what we now consider were too aggressive projections considering its current commercialization resources. We also adjust our updated Fair Value range for an anticipated equity issue.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.


IRRAS - Estimates Revision

Författare MFN